The human large B-cell lymphoma cell line RC-K8 has a rearranged REL locus that directs the production of a chimeric protein, termed REL-NRG (Non-Rel Gene). In this study, we show that RC-K8 cells have constitutively nuclear heterodimeric and homodimeric DNA-binding complexes that consist of p50, REL, and REL-NRG. In vitro, IkBa can block the DNA-binding activity of wildtype REL homodimers but not REL-NRG homodimers. In vivo, REL-NRG cannot activate transcription of a kB site reporter plasmid, suggesting that it is a transcription repressing or blocking REL protein. By Western blotting, no IkBa protein can be detected in extracts of RC-K8 cells. The absence of IkBa protein in RC-K8 cells appears to be due to mutations that cause premature termination of translation in three of the four copies of the IKBA gene in RC-K8 cells. Re-expression of wild-type IkBa or a super-repressor form of IkBa in RC-K8 cells is cytotoxic; in contrast, expression of a dominant-negative form of IkB kinase does not affect the growth of RC-K8 cells. By cDNA microarray analysis, a number of previously identified Rel/NF-kB target genes are overexpressed in RC-K8 cells, consistent with there being transcriptionally active REL complexes. Taken together, our results suggest that the growth of RC-K8 cells is dependent on the activity of nuclear wild-type REL dimers, while the contribution of REL-NRG to the transformed state of RC-K8 cells is less clear. Nevertheless, the RC-K8 cell line is the first tumor cell line identified with mutations in genes encoding multiple proteins in the Rel/NF-kB signal transduction pathway.
Introduction
The Rel/NF-kB family of transcription factors regulates the transcription of numerous genes involved in myriad cellular and physiological processes, including apoptosis, inflammation, immune responses, and cell growth (reviewed in Gilmore, 1999a; Pahl, 1999) . In vertebrates, the Rel/NF-kB transcription factors include c-Rel, RelA, RelB, p50/p105 and p52/p100. These proteins bind DNA as heterodimers and homodimers, and are related through a conserved Nterminal domain called the Rel Homology (RH) domain. The RH domain has sequences essential for dimerization, DNA binding, and nuclear localization. c-Rel, RelA and RelB have C-terminal domains that mediate transcriptional activation of target genes.
The activity of Rel/NF-kB transcription factors is regulated by interaction with a family of inhibitor proteins called IkB proteins (reviewed in Karin, 1999) . The IkB proteins include IkBa, IkBb, IkBe, and the full-length versions of the Rel/NF-kB proteins p105 and p100. All IkB proteins contain multiple copies of ankyrin repeats, which interact with the RH domain to block DNA binding by Rel/NF-kB complexes. In addition, the interaction of a Rel/NF-kB complex with an IkB protein generally results in that complex residing primarily in the cytoplasm. Signals that activate NF-kB induce the degradation of IkB, and thus permit the nuclear localization of the active NFkB dimer. Most of these signals activate an IkB kinase (IKK), which is an essential upstream step for degradation of IkB and induction of the Rel/NF-kB pathway. Thus, IkB molecules that cannot be phosphorylated (IkB super-repressors) or dominantnegative versions of IKK often act as inhibitors of Rel/NF-kB induction.
Constitutive activation of the Rel/NF-kB signal transduction pathway has been implicated in several human cancers, especially lymphoid cell malignancies (reviewed in Gilmore et al., 2002) . In particular, amplifications of REL (the human c-rel gene) have been reported in many human diffuse B-cell lymphomas (Barth et al., 1998 (Barth et al., , 2001 Houldsworth et al., 1996; Joos et al., 1996; Lu et al., 1991; Palanisamy et al., 2002; Rao et al., 1998) and in up to 20 -50% of Hodgkin's lymphomas (Joos et al., 2002; Martı´n-Subero et al., 2002) . Furthermore, REL is the only human Rel/NF-kB family member that has been directly shown to be able to transform lymphoid cells in vitro . In addition, some Hodgkin's lymphomas have constitutive, nuclear Rel/ NF-kB DNA-binding activity due to inactivating mutations in the gene encoding IkBa (reviewed in Staudt, 2000) .
RC-K8 is a human cell line derived from a diffuse large B-cell lymphoma (Kubonishi et al., 1986) . RC-K8 cells have many chromosomal alterations (Kubonishi et al., 1986) , including a large deletion on chromosome 2 that generates a hybrid gene locus termed REL -NRG (Non-Rel Gene) (Lu et al., 1991; Kalaitzidis and Gilmore, 2002) . REL -NRG contains exons 1 -7 of REL and 6 exons of the largely uncharacterized NRG gene (Kalaitzidis and , and encodes a chimeric protein containing the N-terminal 284 amino acids of REL fused to 156 amino acids of NRG. Thus, REL-NRG consists of most of the N-terminal DNAbinding and dimerization domain of REL and Cterminal NRG sequences. REL and REL-NRG are both expressed in RC-K8 cells . In vitro-synthesized REL-NRG can form homodimers and bind to DNA, but is lacking the REL nuclear localization sequence (NLS) and the REL C-terminal transactivation domains (Kalaitzidis and . The function of the NRG residues is not known; however, the NRG sequences do not activate transcription when fused to the GAL4 DNAbinding domain (Gilmore et al., 1995) .
In this study, we have further characterized alterations of the Rel/NF-kB pathway that have occurred in RC-K8 cells. Our results show that the Rel/NF-kB pathway is constitutively active in RC-K8 cells, and that, in addition to the deletion that has occurred in REL, there are mutations that lead to the inactivation of the gene encoding IkBa. As such, this study reports the first identification of a cell line that has mutations in more than one gene encoding a protein in the Rel/ NF-kB pathway, adding to the body of evidence that incriminates the misregulation of this pathway in the development of human lymphoid cell malignancies.
Results

RC-K8 cells have constitutively nuclear DNA-binding complexes that contain p50, REL and REL-NRG
Because normal mature B cells and many tumor cells have constitutively active, nuclear Rel/NF-kB DNAbinding activity , we investigated whether RC-K8 cells might also have such activity. Electrophoretic mobility shift assays using a kB site probe showed that RC-K8 nuclear extracts do have readily detectable amounts of constitutive kB site binding activity, which is comparable to the elevated levels seen in EBV-transformed human B cells (CahirMcFarland et al., 2000) (Figure 1a) .
Supershift analysis indicates that the complexes from RC-K8 cells contain p50 and REL, but not RelA, RelB or p52 (Figure 1b) . However, some DNA-binding activity could not be supershifted by either p50 antiserum or antiserum directed against NLS sequences of REL (that are not present in REL-NRG). This residual complex from RC-K8 cells co-migrated with a complex formed by in vitro-translated REL-NRG, which was also not supershifted by the same anti-REL antiserum. Thus, we believe the complex from RC-K8 cells that cannot be supershifted by any Rel/ NF-kB antiserum consists of REL-NRG homodimers. Taken together, these data suggest that RC-K8 cells have constitutively active kB site binding activity that consists of p50/p50, p50/REL, p50/REL-NRG, REL/ REL and REL-NRG/REL-NRG, and possibly REL/ REL-NRG dimers.
The presence of nuclear DNA-binding REL-NRG homodimers was somewhat surprising because REL- Figure 1 RC-K8 cells have constitutively active nuclear kB site DNA-binding activity that consists of p50, REL and REL -NRG. (a) Nuclear extracts containing 9 mg of protein from RC-K8 and EBV-transformed human B cells were analysed in an EMSA using a kB site probe, as described in Materials and methods. Only the portion of the gel containing the shifted complex is shown. (b) A kB site EMSA was performed as in (a) using either 4 ml of in vitro-translated proteins (WGE, non-programmed wheat germ extract; REL; REL -NRG) or 8 mg of RC-K8 nuclear extract (RC-K8). Supershift analysis was performed using the indicated antisera. The positions of the various complexes are indicated. (c) Cytosolic (C) and nuclear (N) fractions of RC-K8 cells were analysed by Western blotting using antibodies against RH domain sequences of REL (top panel), p50 (middle panel), and IkBb (bottom panel). The IkBb Western blot was performed after stripping the p50 filter NRG does not contain the REL NLS and because REL-NRG is primarily localized in the cytoplasm when overexpressed in chicken embryo fibroblasts (CEF) . Therefore, we sought to directly demonstrate that some REL-NRG was in the nucleus of RC-K8 cells. Analysis of nuclear and cytoplasmic fractions from RC-K8 cells showed that p50, REL, and REL-NRG can be detected in both cytoplasmic and nuclear fractions ( Figure 1c) . As a control, we show that these nuclear fractions do not contain IkBb (Figure 1c) , which has been shown previously to be located primarily in the cytoplasm (Malek et al., 2001) .
REL-NRG homodimers are resistant to inhibition by IkBa
IkBa can both block binding of REL complexes to DNA and remove pre-established REL complexes from DNA by binding to multiple sequences within the RH domain (Ghosh and Karin, 2002) . As Cterminal sequences of the RH domain (including the NLS) are deleted in REL-NRG, we sought to determine whether IkBa could affect the DNA-binding activity of REL-NRG dimers. In these experiments, wild-type REL or REL-NRG was translated in vitro, and each was then incubated with increasing concentrations of in vitro-translated IkBa either before or after the REL proteins were incubated with the kB site probe (to determine whether IkBa could block binding or remove complexes from DNA, respectively). As shown in Figure 2a , IkBa efficiently inhibited DNA binding by wild-type REL and removed wild-type REL complexes from DNA. In contrast, at similar concentrations IkBa neither blocked DNA binding by REL-NRG nor removed REL-NRG complexes from DNA. Furthermore, the addition of in vitro-translated IkBa to extracts from RC-K8 cells inhibited DNA binding by the most slowly migrating REL-containing complex (REL/ REL), but not by REL-NRG or p50-p50 homodimers (Figure 2b ). These results indicate that in vitro-and in vivo-synthesized REL-NRG is resistant to the activity of IkBa.
REL -NRG cannot activate transcription from a kB site reporter plasmid
We next determined whether REL-NRG could activate transcription from a kB site-dependent reporter gene in two cell types: in cells that have low levels of endogenous kB site transactivation (A293 cells) and in cells that have high levels of kB site transactivation activity (CEF) (Figure 3 ). In these assays, cells were co-transfected with expression plasmids for wild-type human REL or for REL-NRG and with a kB site-containing luciferase reporter plasmid. In A293 cells (Figure 3a) , wild-type REL activated transcription of the reporter plasmid, as compared to the empty vector control. In contrast, REL-NRG did not activate transcription of the kB site reporter plasmid in A293 cells, and actually slightly reduced the already low level of transactivation seen with the control vector.
Previous results have shown that kB site reporter genes are highly active in CEF (Kralova et al., 1994; Richardson and Gilmore, 1991) , no doubt due to a constitutively active Rel/NF-kB complex in these cells. Expression of Rel proteins can reduce transactivation from kB site reporter plasmids in CEF (Capobianco and Gilmore, 1991; Kralova et al., 1994; Richardson and Gilmore, 1991) , presumably because they replace a more highly transactivating Rel/NF-kB family member, such as RelA. Similar to these previous results, co-expression of wild-type REL reduced the high level of transactivation seen with empty vector in CEF (Figure 3b ). Co-expression of REL-NRG further reduced the level of reporter gene activation seen in CEF. As a control, we analysed the effect of REL-NRG on RSV-Luc, a reporter plasmid containing the Rous sarcoma virus long terminal repeat (LTR) driving the luciferase gene; the RSV LTR is not known to contain kB sites and we have previously shown that chicken c-Rel does not affect transcription from the RSV LTR (Capobianco and Gilmore, 1991) . REL-NRG did not reduce transcription from RSV-Luc (Figure 3c ), suggesting that REL-NRG is not a general repressor of reporter gene activity.
Taken together, the results in this section suggest that REL-NRG does not activate kB site promoters/ enhancers under conditions where such sequences are weakly or highly active.
No IkBa protein is detectable in RC-K8 cell extracts and there are inactivating mutations in the IKBA gene in RC-K8 cells
Because of the constitutive kB site binding activity in RC-K8 nuclear extracts, we examined RC-K8 cell extracts for the presence of IkB proteins. Curiously, no IkBa was detected in Western blotting of RC-K8 cell extracts using antisera directed against either N-or C-terminal sequences of IkBa (Figure 4a ). These antisera could easily detect IkBa in extracts from EBV-transformed human B cells ( Figure 4 ) and from HeLa cells (data not shown). Furthermore, there were readily detectable levels of IkBb and IkBe in RC-K8 cells (Figure 4) .
By Northern blotting, an apparently full-length IKBA mRNA is expressed in RC-K8 cells, and the level of IKBA mRNA is only slightly lower than that seen in EBV-transformed B cells ( Figure 5a ). Moreover, IKBA mRNA is detected by cDNA microarray analysis of RC-K8 cells (see below).
Because mutations that inactivate the gene encoding IkBa have been found in several Hodgkin's lymphoma cells (Cabannes et al., 1999; Emmerich et al., 1999; Jungnickel et al., 2000) and because no IkBa protein was present in Western blots of RC-K8 cell extracts, we were interested in determining whether the IKBA mRNA from RC-K8 cells could direct the synthesis of an intact IkBa protein. Therefore, we used RT -PCR to amplify IkBa cDNA from RC-K8 cells, and included a T7 promoter element on the 5' PCR primer to allow us to subject the pooled cDNA to in vitro transcription/translation (Den Dunnen and van Ommen, 1999) . As a control, we also amplified IkBa cDNA from EBV-transformed cells, which synthesize wild-type IkBa (see Figure 4) . In vitro translation of the pooled IkBa cDNA from RC-K8 mRNA yielded three products in approximately equal abundance: an apparently full-length 36 kDa protein, an approximately 18 kDa protein, and an approximately 10 kDa polypeptide (Figure 5b ). In contrast, the pooled IkBa cDNA from EBV-transformed cells yielded only the predicted wild-type 36 kDa polypeptide (Figure 5b) .
Subcloning of several IkBa cDNAs from the RC-K8 cDNA pool identified individual cDNAs that uniquely directed the synthesis of the 36, 18 and 10 kDa polypeptides (Figure 5b ). DNA sequencing of these cDNAs identifed four types: one that is wild-type; one with a point mutation at nucleotide (nt) 554 that creates a stop codon at codon 154 (CAG?TAG); one with a deletion of a C residue at nt 272 that generates a frame-shift mutation in codon 60 resulting in a stop codon at nt 360; and one with both of these mutations (nt numbering is according to the cDNA sequence in Haskill et al., 1991) . The cDNA with the mutation in codon 154 is predicted to encode a polypeptide of approximately 18 kDa, and the two cDNAs with the frame-shift mutation in codon 60 encode polypeptides of only 88 residues (or about 10 kDa). Thus, these four classes of cDNAs can account for the proteins seen by in vitro translation of the pooled RC-K8 IkBa cDNA.
To confirm that these mutations exist in genomic DNA, intron primers were used to amplify the corresponding IKBA sequences from RC-K8 genomic DNA, which were then subcloned and sequenced. As shown in Figure 6 , the analysis of multiple subclones from genomic DNA enabled us to identify four distinct genomic products that correspond to the cDNAs: one that had wild-type sequences at codons 60 and 154; one with a deleted C residue in codon 60 (in exon 1); one with a stop codon mutation in codon 154 (in exon 3); and one with both of these mutations (in exons 1 and 3). These results confirm the RT -PCR results, i.e., that genomic loci exist that correspond to the IkBa RT -PCR products. Moreover, they indicate that there are four IKBA loci in RC-K8 cells.
Expression of wild-type IkBa or the IkBa super-repressor slows the growth of RC-K8 cells
Because no IkBa protein could be detected in RC-K8 cells, we sought to determine whether re-expression of IkBa would affect the growth of RC-K8 cells. Therefore, RC-K8 cells were infected with retroviruses encoding wild-type IkBa or a super-repressor form of IkBa (in which the sites of phosphorylation by IKK have been mutated to render it resistant to signalinduced degradation). As shown in Figure 7 , both forms of IkBa were cytotoxic to RC-K8 cells. In contrast, expression of wild-type or a dominantnegative form of the IkB kinase b (IKKb) did not affect the viability of RC-K8 cells (Figure 7 ). IkBa cDNA was amplified by RT -PCR and then re-amplified by PCR using a 5' primer that also contained the T7 promoter sequence. The T7 promoter-containing cDNAs (Total cDNA) were then transcribed and translated in vitro. In the lanes designated 'RC-K8 subclones', individual IkBa cDNAs were subcloned into pGEM and were then transcribed and translated in vitro. Bands were visualized by phosphorimaging. The mutation status of each subclone was determined by DNA sequencing of the cDNA: X, stop codon; fs, frameshift (see also text and Figure 6 ). Relevant bands are indicated by arrows Figure 6 RC-K8 cells contain one wild-type and three mutant IKBA alleles. IKBA exons 1 -3 from RC-K8 cells were amplified by PCR, were subcloned, and individual subclones were sequenced using intronic primers. The analysis of several independent subclones identified four classes of IKBA genes, which corresponded to the cDNA sequences that were identified after RT -PCR (see Figure 5) . The relevant portions of the sequences of exons 1 and 3 are shown. The P60fs mutation is missing a C residue (underlined gap), creating a frameshift mutation that is predicted to encode an 88 amino acid, truncated IkBa protein.
The Q154X mutation has a C to T transition that creates a stop codon at codon 154 as indicated Figure 7 Expression of IkBa is cytotoxic in RC-K8 cells. Equal number of cells were infected with a retroviral vector containing either wild-type IkBa (IkB, WT), IkBa S32G/S36A (IkB, SS), wild-type IKKb (IKKb, WT), dominant-negative IKKb (IKKb, K44A), or no insert (empty vector). Live infected cells were quantified on the days indicated by flow cytometry using an FITC-conjugated antibody to CD8a (Lyt2), ethidium, and beads, as described in Materials and methods. Values were normalized to day 2 values Rel/NF-kB pathway in RC-K8 cells D Kalaitzidis et al RC-K8 cells have increased expression of many mRNAs that are known to be activated by Rel/NF-kB DNA-binding complexes
We have previously shown that the subset of human diffuse large B-cell lymphomas (Activated B Cell-like (ABC) DLBCLs) that have high levels of constitutive NF-kB activity also show increased expression of a number of Rel/NF-kB target genes as compared to germinal center-like (GCB) DLBCLs in which NF-kB is not as active (Davis et al., 2001) . As shown in Figure  8a , RC-K8 cells also have considerably more nuclear kB site binding activity than the previously characterized GCB DLBCL cell line SUDHL-4.
Because RC-K8 cells have constitutively nuclear REL and REL-NRG complexes (Figure 1 ), we were interested in determining whether RC-K8 also had increased expression of Rel/NF-kB target genes as compared to GCB-like DLBCLs. As shown in Figure  8b , many of the same NF-kB target genes that show increased expression in ABC DLBCL cell lines (OCILy3 and OCI-Ly10; see also Davis et al., 2001) are also expressed in RC-K8 cells to a higher level than in several GCB cell lines. Among others, the Rel/NF-kB target genes with increased expression in RC-K8 cells include genes encoding anti-apoptosis proteins (A20, Bcl-X L , Bfl-1/A1, TRAF-1, TRAF-2), cytokines and surface receptors (TNF-a, lymphotoxin-a, CCR-7, CD-40 and CD83), Rel signaling proteins (NF-kB2/p100, IkBa), and proteins implicated in oncogenesis (IRF-4).
Discussion
In this study, we show that there are multiple genetic alterations in the Rel/NF-kB/IkB signaling pathway in the RC-K8 human lymphoma cell line. In addition to the previously characterized chromosomal alteration that leads to the production of a mutant REL protein (REL-NRG), RC-K8 cells have mutations in the IKBA gene that inactivate the IkBa protein. These genetic alterations result in constitutively nuclear REL and REL-NRG DNA-binding complexes, which apparently increase the expression of several Rel/NF-kB target genes that are required for the growth and survival of RC-K8 cells. That is, cDNA microarray analysis reveals that several Rel/NF-kB target genes show increased expression in RC-K8 cells and re-expression of IkBa in these cells inhibits their growth. These findings emphasize the extent to which genes in the Rel/NF-kB pathway may be subject to mutations associated with oncogenesis, underscore the contribution of mutations in this pathway to the development of human lymphoid cell malignancies, and are consistent with the accumulating evidence that this pathway is a therapeutic target in many B-cell malignancies.
The RC-K8 cell line was derived from a patient with a cancer described as a diffuse large B-cell lymphoma (DLBCL) (Kubonishi et al., 1986) . Alizadeh et al. (2000) have shown that DLBCLs can be subdivided into at least two classes based on their mRNA expression profiles: one that expresses genes in a pattern similar to activated B cells (ABC) and one that expresses genes in a pattern similar to germinal center B cells (GBC). More recently, Davis et al. (2001) have shown that ABC DLBCLs have enhanced levels of constitutively active nuclear NF-kB complexes that Figure 8 RC-K8 cells have increased nuclear DNA-binding activity and expression of several Rel/NF-kB target genes as compared to GCB DLBCL cell lines. (a) EMSA of nuclear extracts (4 mg of protein) from RC-K8 cells and SUDHL-4 cells. The experiment was performed as described for Figure 1 , and the shifted complex is shown. (b) Lymphochip microarray mRNA expression data for RC-K8, the seven indicated DLBCL lines of GCB subtype and the two DLBCL lines of ABC subtype (OCI-Ly3 and OCI-Ly10) were examined for known NF-kB target genes. Fourteen NF-kB target genes were identified for which the mRNA level in RC-K8 was at least twofold higher than the average of the GCB type cell lines. Relative values for each gene (rows) were median-centered across all lines (columns), and are shown according to the color scale with red, black, and green for expression level (high, moderate, and low, respectively), and gray for unreliable data. Each value is the average of two array spots, except for lymphotoxin-a (one spot). Genes are arranged by the average difference between RC-K8 and the GCB lines, with the most different at the top. GCB lines are arranged by the average difference from RC-K8 for all the genes shown, with the most different at the right. References for these genes as Rel/NF-kB target genes can be found at http://www.nf-kb.org (under Target Genes) include p50, RELA and REL, and express increased levels of a number of Rel/NF-kB target genes, as compared to GCB DLBCLs. In the two ABC DLBCL cell lines studied therein, the constitutive Rel/NF-kB activity is due to chronic activation of the IKK complex and, thus, the growth of these ABC DLBCL cell lines could be preferentially blocked by molecular inhibitors of the NF-kB pathway, including both the IkBa super-repressor and a dominant-negative IKKb (Davis et al., 2001) . Our results with the RC-K8 cell line indicate that the Rel/NF-kB pathway can also be activated in DLBCLs by mutations that inactivate the function of IkBa. Thus, in this respect, DLBCLs may be similar to Hodgkin's lymphomas that also have constitutively active Rel/NF-kB, which can be a consequence of either increased IKK activity, inactivating mutations in the IKBA gene, or amplification of REL (reviewed in Staudt, 2000; see also Joos et al., 2002; Martı´n-Subero et al., 2002) .
Consistent with the lack of IkBa being the primary cause of the constitutive nuclear Rel/NF-kB DNAbinding activity in RC-K8 cells, overexpression of wildtype or super-repressor forms of IkBa, but not wild-type or dominant-negative IKKb is cytotoxic in RC-K8 cells (Figure 7) . Thus, RC-K8 cells differ from ABC DLBCLs in their response to molecular inhibitors of the Rel/NFkB pathway in two ways. First, RC-K8 cells are killed by overexpression of both wild-type and super-repressor IkBa, whereas only super-repressor IkBa is toxic in ABC DLBCLs (Davis et al., 2001) . Second, the proliferation of RC-K8 cells is not affected by expression of a dominant-negative IKKb, which is cytotoxic for ABC DLBCLs (Davis et al., 2001) . These results suggest that various lymphoid cell cancers will respond differently to inhibitors that target distinct points in the Rel/NF-kB signaling pathway, and that loss of IkBa expression (e.g., by mutation of the IKBA gene) may circumvent therapeutic inhibition of IKK activity.
The constitutive nuclear kB site DNA-binding activity in RC-K8 cells consists of complexes that contain wild-type REL, REL-NRG and p50. Of these, only complexes containing wild-type REL are inhibited by IkBa. Thus, the ability of overexpressed IkBa to be toxic to RC-K8 cells suggests that the nuclear complexes containing REL are required for the viability of these cells. In contrast, IkBa does not inhibit DNA binding by p50 or REL-NRG homodimers. Thus, it is not clear whether p50 or REL-NRG complexes contribute to the growth of RC-K8 cells.
Our cDNA microarray analysis (Figure 8b ) indicates that several Rel/NF-kB target genes show enhanced expression in RC-K8 cells. Nevertheless, the list of activated Rel/NF-kB target genes in RC-K8 cells differs somewhat from that found in ABC DLBCLs (Alizadeh et al., 2000; Davis et al., 2001) . There are several possible explanations for these differences. First, ABC DLBCLs have primarily nuclear p50-RELA complexes, whereas the RC-K8 cells have largely REL complexes. Second, RC-K8 cells also have nuclear complexes containing REL-NRG, which our results indicate is a repressor of kB site-dependent transcription. Lastly, there are no doubt transcription factors other than Rel/NF-kB that are required for full expression of many Rel/NF-kB target genes, which may account for differences among cell lines and individual lymphoma samples.
RC-K8 cells have been reported to have only one copy of chromosome 14 (Kubonishi et al., 1986) on which the IKBA gene is located (Le Beau et al., 1992) . Nevertheless, our results indicate that there are four copies of the IKBA gene in RC-K8 cells. Thus, there may be a local expansion of the IKBA gene in RC-K8 cells. One copy of the IKBA gene appears to be wildtype in RC-K8 cells, while three copies have mutations that encode truncated IkBa proteins. Interestingly, one of the IKBA genes has both of the mutations that are present as single copies in two of the other loci, suggesting that there may have been an intergenic duplication at some point.
In spite of extensive efforts, including treatment of cells with proteasome and calpain inhibitors (data not shown), we have not been able to detect any wild-type IkBa protein in RC-K8 cells, even though some wildtype IkBa mRNA is expressed in these cells and there is one wild-type copy of the IKBA genomic locus (Figures 5 and 6 ). Thus, it appears either that the levels of wild-type IkBa are below our level of detection, that IkBa is a highly unstable protein in RC-K8 cells, or that the presence of the mutant IkBa mRNAs blocks translation of the wild-type IkBa mRNA. Notably, in some Hodgkin's lymphomas, it appears that there is one mutant and one wild-type copy of the IKBA gene (Jungnickel et al., 2000) .
Why might RC-K8 cells have acquired and maintained mutations in both IKBA and REL? Of course, these mutations could be random events that do not contribute to the growth or transformed state of RC-K8 cells. However, the identification of mutations in IKBA in Hodgkin's lymphomas and the ability of forced IkBa expression to block the growth of RC-K8 cells suggest that the mutations in IKBA contribute to some B-cell malignancies. In one scenario, the mutation that created REL-NRG may provide RC-K8 cells with both activating and repressing REL complexes that contribute to the malignant state. That is, a balance between REL-controlled target gene activation and REL-NRG-mediated target gene repression might be optimal for the transformed state of RC-K8 cells. Consistent with this model, the highly transforming v-Rel oncoprotein has a C-terminal deletion that reduces its transactivation ability (as compared to wild-type chicken c-Rel), and v-Rel is known to both activate and repress target genes (reviewed in Gilmore, 1999b) . Similarly, c-Rel can both activate and repress transcription Grigoriadis et al., 1996) and our results show that REL-NRG is a more effective repressor of transcription than wild-type REL (Figure 3 ). Although we have recently shown that wild-type human REL can transform chicken lymphoid cells in vitro , REL-NRG does not, by itself, appear to be able to transform these cells (unpublished results).
In summary, our results show that the diffuse large B-cell lymphoma cell line RC-K8 has alterations in two genes, REL and IKBA, in the Rel/NF-kB signal transduction pathway. Both of these mutations contribute to the constitutive nuclear kB site DNAbinding activity that is present in these cells. Thus, the RC-K8 cell line may be an important model for the molecular analysis of the contribution of altered REL protein activity in human lymphomas.
Materials and methods
Cells
RC-K8 cells, EBV-transformed human B cells (cell line IB4), SUDHL-4, A293 human embryonic kidney cells, and chicken embryonic fibroblasts (CEF) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 -20% fetal bovine serum, 50 units/ml penicillin, and 50 mg/ml streptomycin.
Plasmids
pcDNA3.1(+) is from Invitrogen (Carlsbad, CA, USA). pCMV-REL and pCMV-REL-NRG were kind gifts of Inder Verma (Salk Institute). 36kB-luc and pGK-bgal have been described previously (Sylla et al., 1998) ; RSV-Luc was a kind gift of Ulla Hansen (Boston University). pGEM plasmids for the in vitro expression of human IkBa, REL, and REL-NRG have been described previously (Barkett et al., 1997 (Barkett et al., , 2001 ).
Preparation of protein extracts and Western blotting
Whole cell extracts were obtained by resuspending cell pellets in SDS-sample buffer (62.5 mM Tris, pH 6.8, 3.2% w/v sodium dodecyl sulphate, 10% w/v glycerol, 5% v/v bmercaptoethanol, 0.1% w/v bromophenol blue), heating samples at 958C for 10 min, and clarifying them by centrifugation for 10 min at 14 000 g. Nuclear and cytoplasmic extracts were prepared as described previously (Schreiber et al., 1989) with the inclusion of 1 mM DTT, 5 mg/ml leupeptin, 62.5 mg/ml aprotinin, 1 mg/ml pepstatin and 1 mM PMSF. Protein concentrations were determined using the Bio-Rad (Hercules, CA, USA) protein assay reagent, and measuring absorbance at 595 nm.
For Western blotting, extracts were separated on SDSpolyacrylamide gels, transfered to nitrocellulose membranes (Osmonics, Westborough, MA, USA) probed, and visualized using the Pierce SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford, IL, USA). Antibodies for IkBa (sc-371 and sc-203), IkBb (sc-946), IkBe (sc-7156), p50 (sc-7178), and actin (sc-1616) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Human REL antibody used for Western blotting was raised against the epitope KAGINPFNVPEKQLNDIE, and was a kind gift of Nancy Rice (see Kalaitzidis and Gilmore, 2002) .
Electrophoretic mobility shift assay
EMSAs were performed using nuclear extracts prepared as described above or in vitro-translated proteins. DNA-binding reactions were in a final volume of 50 ml containing 10 mM Tris, pH 7.4, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 4% w/ v glycerol, 10 mg bovine serum albumin, 2 mg poly dI/dC, 10 000 c.p.m. of 32 P-end-labeled kB probe (5'-TCGA-GAGGTCGGGAAATTCCCCCCCG-3'), and either 4 -10 mg of nuclear extract or 2 -4 ml of in vitro-translated protein. DNA/protein complexes were incubated at room temperature for 30 min. Complexes were resolved on 5.6% polyacrylamide Tris-glycine-EDTA gels, and were electrophoresed at 60 mA for approximately 1.5 h. Gels were dried and autoradiography was performed. For supershift assays, 1 ml of antiserum was added after protein/DNA complex formation and the reactions were incubated on ice for 1 h. Antibodies specific for p50 (sc-7178X), p52 (sc-298X), RelA (sc-372X) and RelB (sc-226X) were purchased from Santa Cruz Biotechnology; the REL supershift antiserum was raised against the epitope DEKDTYGNKAKKQKTTLLFQKL which includes the NLS of REL (a kind gift of Nancy Rice).
For IkBa inhibition studies, in vitro-translated IkBa was added to nuclear extracts or to in vitro-translated proteins for 1 h on ice prior to the addition of probe or for 1 h on ice after DNA/protein complex formation.
Luciferase reporter assays
A293 cells in 35 mm plates were transfected with 0.5 mg of 36kB-luciferase reporter plasmid, 0.5 mg of pGK-bgal, and 1 mg of expression plasmid using the Superfect Reagent according to the manufacturer's recommendations (Qiagen, Valencia, CA, USA). CEF in 35 mm plates were transfected using the DMSO/polybrene method with 2 mg of 36kB-luc or RSV-Luc, 2 mg of pGK-bgal and 4 mg of expression plasmid. Luciferase activity was measured using the Luciferase Assay System according to manufacturer's instructions (Promega, Madison, WI, USA). b-galactosidase activity was measured as described previously (Sylla et al., 1998) , and luciferase levels were normalized to b-galactosidase values in all assays. mRNA analysis: Northern blotting and microarray analysis For Northern blotting, mRNA was obtained from RC-K8 cells or EBV-transformed cells using the poly(A) + pure kit according to manufacturer's instructions (Ambion, Austin, TX, USA). The amounts of the two mRNA pools were first normalized by electrophoresis on a 1% agarose gel and staining with ethidium bromide. Equal amounts of total mRNAs were then electrophoresed on a 1.5% agarose gel containing formaldehyde, and were transferred to a Hybond N + filter (Amersham, Buckinghamshire, UK). An IkBa cDNA was used as template for probe production and was labeled with 32 P using the random-primed DNA labeling kit according to manufacturer's instruction (Boehringer Mannheim, Indianapolis, IN, USA). Northern blotting was performed according to standard protocols (Sambrook et al., 1989) and bands were detected by autoradiography.
cDNA microarray analysis of gene expression was performed using Lymphochip microarrays, as described previously (Alizadeh et al., 2000) . Briefly, mRNA from RC-K8 cells was labeled with Cy5 dUTP in a first-strand cDNA reaction, and a reference cDNA probe, labeled with Cy3 dUTP, was prepared using mRNA from a pool of nine lymphoma cell lines. Following hybridization of these two cDNA probes to a Lymphochip DNA microarray (Alizadeh et al., 1999) , the arrays were washed, and bound fluorescent probe was detected using an Axon GenePix Scanner. The ratio of the pixel intensities for Cy5 and Cy3 fluorescence was calculated for each array element. For a given gene, these ratios were median-centered prior to display using a color scheme as described (Eisen et al., 1998) .
cDNA synthesis, subcloning, in vitro transcription/translation and DNA sequencing cDNA was synthesized using mRNA from RC-K8 cells using a polydT primer and AMV reverse transcriptase according to the manufacturer's instructions (Promega). IkBa cDNA was then amplified using the forward primer 5'-CCCAGCGAG-GAAGCAGCG-3' and reverse primer 5'-AGTCCATGTT-CTTTCAGCCCC-3' using the GC-Rich PCR system according to the manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN, USA). To prepare a pool of IkBa cDNA for in vitro translation and subcloning, respectively, IkBa cDNA was used as template in PCRs using either a 5' T7 promoter-containing primer (5'-TAATACGACTCACTATAGGGCCCAGCGAGGAAG-CAGCG-3'; T7 promoter underlined) and the reverse primer 5'-AGTCCATGTTCTTTCAGCCCC-3', or a forward EcoRI site-containing primer (5'-CGGAATTCCGCCCAGCGAG-GAAGCAGCG-3') and a reverse BamHI site-containing primer (5'-CGCGGATCCGCGAGTCCATGTTCTTTCAG-CCCC-3'). IkBa cDNA was then digested with EcoRI and BamHI, and subcloned downstream of the SP6 promoter in the corresponding sites of pGEM4 (Promega). Subclones were sequenced in both directions by automated sequencing using PCR primers used to obtain the cDNA, the forward primer 5'-ATCGTGGAGCTTTTGGTGTC-3', and the reverse primer 5'-GTTGACATCAGCCCCACAC-3', according to standard protocols.
T7 PCR products or individual subclones were used as templates for in vitro transcription/translation reactions in the presence of Tran 35 S-label (Amersham) using rabbit reticulocyte lysate for the T7 promoter templates or wheat germ extract for the SP6 promoter templates according to manufacturer's instructions (Promega) and as described previously .
Genomic DNA was isolated from RC-K8 cells according to standard protocols (Ausubel et al., 1995) . A fragment containing IKBA exons 1 -3 was amplified by PCR from genomic DNA using a forward primer (5'-CGCG-GATCCGCGCCAGCCAGCGTTTATAGGG-3') and a reverse primer (5'-CGCGGATCCGCGCAACCCTCACT-CCTTTCACC-3'), both containing BamHI sites (underlined), and the GC-Rich PCR system (Roche Molecular Biochemicals). The PCR product containing IKBA exons 1 through 3 was digested with BamHI, subcloned into the BamHI site of pGEM4, and sequenced using forward primer 5'-CCAGC-CAGCGTTTATAGGG-3' and reverse primer 5'-CATCG-CTGGTCCCCCGGCTC-3' for exon 1, and forward primer 5'-CTGGAGCCTCTGCTATTTGC-3' and reverse primer 5'-CAACCCTCACTCCTTTCACC-3' for exon 3.
Retroviral preparation and transduction
The retroviral vector pBMN-Ires-Lyt2 (vLyt2, kindly provided by G. Nolan, Stanford University) contains a subcloning site followed by the ECMV IRES element and the coding region of mouse CD8a (Lyt-2). Forms of vLyt2 were prepared to express human IkBa, either wild-type or a superrepressor mutant with S32G/S36A changes (Brown et al., 1995; Davis et al., 2001) . Forms of vLyt2 were also prepared to express human IKKb, either wild-type or kinase-inactive due to a K44A mutation. Phoenix amphotropic producer lines (also provided by G Nolan) were transfected with vLyt2 by the calcium phosphate method, and 2 days later the supernatant was used for transduction by spin-infection as previously described (Quong et al., 1999) .
Survival analysis of transduced cells
Enumeration of live cells after vLyt-2 retroviral transduction was performed as previously described (Davis et al., 2001) . In brief, cells in measured aliquots of cultures at various time points were stained with FITC-conjugated anti-mouse CD8a and ethidium homodimer-1. These were analysed by flow cytometry after addition of a known quantity of polystyrene beads. Live transduced cells (Lyt-2-positive) were identified on the basis of light scatter, low staining by ethidium (red fluorescence), and positive FITC fluorescence; beads were identified by their distinctive combination of low forward and high side scatter. The total number of Lyt-2-positive live cells in the original culture was then determined from the relative numbers of beads and positive cells identified in the analysis, the concentration of beads in the bead suspension, and the volumes of original cultures and aliquots.
